Journal
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Volume 26, Issue 5, Pages 497-501Publisher
MARY ANN LIEBERT INC
DOI: 10.1089/jop.2010.0013
Keywords
-
Categories
Funding
- Department of Science and Technology of Guangdong Province [2005B30901019]
- Ministry of Education of China, People's Republic of China [20060558031]
Ask authors/readers for more resources
Objectives: We aimed to investigate whether CYP2D6 polymorphisms were associated with the intraocular pressure (IOP)-lowering effect and systemic complications (especially bradycardia) of ophthalmic timolol. Methods: One hundred twenty-three primary open-angle glaucoma subjects (123 eyes) were treated with 0.5% aqueous formulations of ophthalmic timolol. IOP and heart rate were measured before and after timolol administration. DNA was extracted from venous leukocytes of all the subjects. Two single-nucleotide polymorphisms (SNPs) of CYP2D6, for example, rs16947 (2850C>T, R296C) and rs1135840 (4180C>G, S486T), were detected by restriction fragment length polymorphism analysis. Results: Neither rs16947 (P=0.339) nor rs1135840 (P=0.903) genotype was statistically correlated with the IOP-lowering effect of timolol eye drops. The rs16947 genotype was significantly associated with occurrence of bradycardia in primary open-angle glaucoma patients (P=0.021). The patients with rs16947 CT (P=0.043) or TT (P=0.043) were more inclined to bradycardia than those with rs16947 CC, although there was no significant difference between CT and TT (P=0.177). The analysis of variance showed no significant difference in heart rate (P=0.559) among GG, GC, and CC groups. Conclusions: CYP2D6 SNP rs16947 may confer susceptibility to timolol-induced bradycardia. Patients with CC genotype were unlikely to suffer from timolol-induced bradycardia, whereas those with TT genotype were found to suffer from timolol-induced bradycardia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available